Evidence map›Paper›PMID 41969229›Full record

ReviewBJU international2026

Oligoprogressive renal cell carcinoma: What is the role of surgery?

Chiara Re, William H J Ince, Leo Bickley, James P Blackmur, Mouhamad H Ismail, Justicia Kyeremeh, Teele Kuusk, Eva Mendes Serrao, James O Jones, Grant D Stewart

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chiara ReDepartment of Surgery, University of Cambridge, Cambridge Biomedical Centre, Cambridge, UK.
William H J InceCRUK Cambridge Centre, University of Cambridge, Cambridge, UK.
Leo BickleyDepartment of Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
James P BlackmurDepartment of Urology, Western General Hospital, Edinburgh, UK.
Mouhamad H IsmailCRUK Cambridge Centre, University of Cambridge, Cambridge, UK.
Justicia KyeremehDepartment of Surgery, University of Cambridge, Cambridge Biomedical Centre, Cambridge, UK.
Teele KuuskDepartment of Surgery, University of Cambridge, Cambridge Biomedical Centre, Cambridge, UK.ORCID 0000-0003-4643-4878
Eva Mendes SerraoDepartment of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
James O JonesCRUK Cambridge Centre, University of Cambridge, Cambridge, UK.
Grant D StewartDepartment of Surgery, University of Cambridge, Cambridge Biomedical Centre, Cambridge, UK.ORCID 0000-0003-3188-9140

Funding

Cancer Research UK Cambridge Centre C9685/A25177Cancer Research UK Cambridge Centre CTRQQR‐2021\100012Department of Health and Social Care RG95043National Institute for Health Research (NIHR) NIHR203312NIHR Cambridge Biomedical Research Centre NIHR203312
6 · The paper itself

Abstract

objectiveTo provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications.

methodsA non-systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and original studies. Additional sources were identified through manual reference screening.

resultsOligoprogression in RCC likely arises from clonal evolution dynamics, with spatially confined subclone mutations and microenvironmental niches yielding differential responses to treatment. Complete metastasectomy may offer a survival benefit, spare patients toxic side effects of systemic therapy, and offers the possibility of histopathological and molecular characterisation of residual disease. Surgery is also particularly important in delayed cytoreductive nephrectomy as the site of oligoprogression. However, this must be weighed against non-negligible surgical morbidity and complication rates. International guidelines recognise the role of surgical resection in the metastatic setting but emphasise low evidence levels and careful patient selection requirements.

conclusionLimited evidence derived from the oligometastatic context constrains optimal patient selection and timing strategies in oligoprogressive RCC. Following the establishment of consensus over definitions and research gaps, future research integrating molecular biomarkers, novel imaging tracers, and multicentre collaborative studies will be essential to develop evidence-based surgical management protocols for this increasingly common clinical scenario.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsNephrectomyDisease ProgressionHumanslocal treatmentmetastasis‐directed therapymetastatic kidney canceroligoprogressionoligorecurrencerenal cell carcinoma

Identifiers

PMID41969229
PMCPMC13371407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.